1h Free Analyst Time
Meningioma - Pipeline Review, H2 2019Speak directly to the analyst to clarify any post sales queries you may have.
Summary
This latest Pharmaceutical and Healthcare disease pipeline guide Meningioma - Pipeline Review, H2 2019, provides an overview of the Meningioma (Oncology) pipeline landscape.
A meningioma is a type of tumor that develops from the meninges, the membrane that surrounds the brain and spinal cord. There are three layers of meninges, called the dura mater, arachnoid and pia mater. Most meningiomas (90%) are categorized as benign tumors, with the remaining 10% being atypical or malignant. There is no obvious cause of a meningioma. However, this type of brain tumor is about three times more common in women than in men. A meningioma can cause symptoms by pressing on the brain or spinal cord.
Report Highlights
This Pharmaceutical and Healthcare latest pipeline guide Meningioma - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Meningioma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Meningioma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Meningioma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Phase 0, Preclinical and Discovery stages are 7, 4, 1, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.
Meningioma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope:
- The pipeline guide provides a snapshot of the global therapeutic landscape of Meningioma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Meningioma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Meningioma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Meningioma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Meningioma (Oncology)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Meningioma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Meningioma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
IntroductionReport Coverage
Meningioma - Overview
Meningioma - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Meningioma - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Meningioma - Companies Involved in Therapeutics Development
Advanced Accelerator Applications SA
AptaBio Therapeutics Inc
AstraZeneca Plc
BNOAT Oncology Inc
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co
Clarity Pharmaceuticals Pty Ltd
Eli Lilly and Co
Merck & Co Inc
Merck KGaA
Ono Pharmaceutical Co Ltd
Pharma Mar SA
Progenics Pharmaceuticals Inc
Recordati SpA
Recursion Pharmaceuticals Inc
Meningioma - Drug Profiles
Meningioma - Dormant Projects
Meningioma - Discontinued Products
Meningioma - Product Development Milestones
Appendix
List of Tables
Number of Products under Development for Meningioma, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Meningioma - Pipeline by Advanced Accelerator Applications SA, H2 2019
Meningioma - Pipeline by AptaBio Therapeutics Inc, H2 2019
Meningioma - Pipeline by AstraZeneca Plc, H2 2019
Meningioma - Pipeline by BNOAT Oncology Inc, H2 2019
Meningioma - Pipeline by Boehringer Ingelheim International GmbH, H2 2019
Meningioma - Pipeline by Bristol-Myers Squibb Co, H2 2019
Meningioma - Pipeline by Clarity Pharmaceuticals Pty Ltd, H2 2019
Meningioma - Pipeline by Eli Lilly and Co, H2 2019
Meningioma - Pipeline by Merck & Co Inc, H2 2019
Meningioma - Pipeline by Merck KGaA, H2 2019
Meningioma - Pipeline by Ono Pharmaceutical Co Ltd, H2 2019
Meningioma - Pipeline by Pharma Mar SA, H2 2019
Meningioma - Pipeline by Progenics Pharmaceuticals Inc, H2 2019
Meningioma - Pipeline by Recordati SpA, H2 2019
Meningioma - Pipeline by Recursion Pharmaceuticals Inc, H2 2019
Meningioma - Dormant Projects, H2 2019
Meningioma - Discontinued Products, H2 2019
List of Figures
Number of Products under Development for Meningioma, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Top 10 Routes of Administration, H2 2019
Number of Products by Stage and Top 10 Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Advanced Accelerator Applications SA
- AptaBio Therapeutics Inc
- AstraZeneca Plc
- BNOAT Oncology Inc
- Boehringer Ingelheim International GmbH
- Bristol-Myers Squibb Co
- Clarity Pharmaceuticals Pty Ltd
- Eli Lilly and Co
- Merck & Co Inc
- Merck KGaA
- Ono Pharmaceutical Co Ltd
- Pharma Mar SA
- Progenics Pharmaceuticals Inc
- Recordati SpA
- Recursion Pharmaceuticals Inc
